2

en Economics of Hospitalization and Medication Therapy for Old COVID-19 Patients; an Experience from a Tertiary Center in Iran Aims: There are controversies about the expenditures imposed on surveillance in the treatment of elderly patients and patients with end-stage disease. The present health economic evaluation study was performed to find the cost-effectiveness of hospitalization and antiviral treatment of COVID-19 in elderly patients. Instrument & Methods: A health economic evaluation as a single-center primary study with a cross-sectional design was performed in Firoozgar Hospital, Tehran, Iran, in 2022. All the hospitalized cases of COVID-19 at 65 years of age and more were eligible for the study. The health outcomes were the length of stay and death. Cost-effectiveness was calculated using the incremental cost-effectiveness ratio. Stata14 was used for data analysis. Findings: Of the admitted patients, 347 cases over 65 were selected for the study. 173 patients (49.86%) were in the age range of 65-74, 69 patients (31.41%) were in the age range of 75-84, and 65 patients (18.73%) were 85 and more. One hundred ninety-nine patients (57.35%) survived, and 148 patients (42.65%) died. The mean of LoS was 11.40±7.01 days, with the mean at the ward being 5.24±5.44 days and at the ICU 6.15±6.94 days. The mean cost of a bed day was 35.41±32.03 dollars, with a right-skewed distribution. Conclusion: A mean cost of 88.711$ is needed for the survival of one patient, assuming that all the ICU-needed patients would die if there was a lack of hospital admission. Considering all ward and ICU admitted patients, 44.854$ is needed to save one old patient's life, assuming this logic. Health Economics,Cost-Effectiveness,Healthcare Providers, 435 439 http://ijwph.daneshafarand.org/browse.php?a_code=A-10-2132-1&slc_lang=en&sid=3 F. Tavassoli 1003194753284600379304 1003194753284600379304 No Student Research Committee, Iran University of Medical Sciences, Tehran, Iran A. Aghabiklooei 1003194753284600379305 1003194753284600379305 No “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Forensic Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran M. Azimi 1003194753284600379102 1003194753284600379102 No “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Internal Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran M. Baghai Wadji 1003194753284600379101 1003194753284600379101 No “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Surgery, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran S.A.Y. Ahmadi 1003194753284600379100 1003194753284600379100 No “Preventive Medicine and Public Health Research Center” and “Psychosocial Health Research Institute”, Iran University of Medical Sciences, Tehran, Iran M. Ameri 1003194753284600379099 1003194753284600379099 Yes “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Forensic Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran